{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-027459","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.492938+00:00","generated_at":"2026-06-23T06:10:47.848004+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Imunon appoints Curis CEO James E. Dentzer to board effective Sept 29, 2022","bullets":["James E. Dentzer appointed as Class II director; board expands to nine members.","Dentzer is President & CEO of Curis, Inc., with over 20 years of biopharma financial leadership.","Receives standard non-employee director compensation plus initial option grant for 2,667 shares vesting over three years.","Board determined Dentzer is independent under SEC and NASDAQ rules."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-027459","json":"https://secwatch.observer/filing/0001493152-22-027459.json","markdown":"https://secwatch.observer/filing/0001493152-22-027459.md","text":"https://secwatch.observer/filing/0001493152-22-027459.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315222027459/0001493152-22-027459-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315222027459/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T06:10:47.848004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"63319695ed","claim":"James E. Dentzer was appointed as Class II Director at Imunon, Inc..","evidence_excerpt":"On October 3, 2022, Imunon, Inc. (the “Company”) announced that the Board of Directors (the “Board”) appointed James E. Dentzer to the Board as a Class II Director effective September 29, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315222027459/0001493152-22-027459-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}